Antiviral developer NanoViricides says it has inked a confidential disclosure agreement with a “leading pharmaceutical company” in Asia to explore collaborating on the Shelton company’s proposed COVID-19 treatment.
NanoViricides, which says it has already identified drug candidates that are active against multiple coronaviruses in cell studies, also said it is in “advanced discussions” with at least two sites that have the capability to test its drug against SARS-CoV-2, the virus that causes COVID-19.